The paper reports on a series of 15 patients with severe rheumatological autoimmune diseases that were treated with a single infusion of CD19 CAR T-cell therapy by the European team with up to 29 months post-treatment follow up The Authors report the treatment appears to be feasible, safe, and
February 22, 2024